Relationship between pulse pressure and Fibrosis-4 score in non-drinking Korean adults using the Korea National Health and Nutrition Examination Survey
Pulse Pressure and fibrosis-4 score
DOI:
https://doi.org/10.12873/Palavras-chave:
Pulse pressure, High PP, Non-invasive hepatic fibrosis, Fibrosis-4 score, Non-alcoholic fatty liver diseaseResumo
Background: The present study was conducted to assess the association between fibrosis-4 score (FIB-4) and pulse pressure (PP) in Korean adults.
Materials and Methods: Data on 4,236 adults aged 20 or older were obtained from the 2020 Korean National Health and Nutrition Examination Survey.
Results: There were several key findings in the present study. First, compared with the quartile 1 (Q1) of FIB-4, the odds ratio (OR) of high PP (PP > 60 mmHg) was significantly higher in Q2 (OR, 3.469; 95% confidence interval [CI], 1.737–6.928), Q3 (OR, 7.256; 95% CI, 3.744–14.061), and Q4 (OR, 16.660; 95% CI, 8.671–32.007). Second, for predicting high PP, the receiver-operating characteristic (ROC) curve analysis for FIB-4 (area under the ROC curve [AUC], 0.787; 95% CI, 0.769–0.804; p < 0.001). In addition, FIB-4 was superior to other non-invasive hepatic fibrosis indices, such as the aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (z = 11.857; p < 0.001) or AST/platelet ratio index (z = 10.024; p < 0.001) for predicting high PP
Conclusions: FIB-4 was positively associated with PP and SBP in Korean adults but was inversely associated with DBP. In addition, FIB-4 was superior to other non-invasive hepatic fibrosis indices for predicting high PP.
Referências
Litwin M, Obrycki Ł, Niemirska A, Sarnecki J, Kułaga Z. Central systolic blood pressure and central pulse pressure predict left ventricular hypertrophy in hypertensive children. Pediatr Nephrol. 2019;34:703–712. Available at: https://doi.org/10.1007/s00467-018-4136-7.
Homan TD, Bordes S, Cichowski E. Physiology, Pulse Pressure. [Updated 2022 Jul 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482408/.
Liu D, Qin P, Liu L, Liu Y, Sun X, Li H, Zhao Y, Zhou Q, Li Q, Guo C, Tian G, Wu X, Han M, Qie R, Huang S, Zhang M, Hu D, Lu J. Association of pulse pressure with all-cause and cause-specific mortality. J Hum Hypertens. 2021;35:274–279. Available at: https://doi.org/10.1038/s41371-020-0333-5.
Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–1357. Available at: https://doi.org/10.1097/01.hjh.0000431740.32696.cc.
Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q, Huang DQ, Zhao C, Zhang J, Liu C, Chang N, Xing F, Yan S, Wan ZH, Tang NSY, Mayumi M, Liu X, Liu C, Rui F, Yang H, Yang Y, Jin R, Le RHX, Xu Y, Le DM, Barnett S, Stave CD, Cheung R, Zhu Q, Nguyen MH. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20:2809–2817. Available at: https://doi.org/10.1016/j.cgh.2021.12.002.
Zisser A, Ipsen DH, Tveden-Nyborg P. Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets? Biomedicines. 2021;9:365. Available at: https://doi.org/10.3390/biomedicines9040365.
Kumar R, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J Clin Transl Hepatol. 2020;8:76–86. Available at: https://doi.org/10.14218/JCTH.2019.00051.
Fierbinteanu-Braticevici C, Purcarea M. Non-biopsy methods to determine hepatic fibrosis. J Med Life. 2009;2:401–406. PMID: 20108754.
Taniguchi T, Sakata Y, Ohtani T, Mizote I, Takeda Y, Asano Y, Masuda M, Minamiguchi H, Kanzaki M, Ichibori Y, Nishi H, Toda K, Sawa Y, Komuro I. Usefulness of transient elastography for noninvasive and reliable estimation of right-sided filling pressure in heart failure. Am J Cardiol. 2014;113:552–558. Available at: https://doi.org/10.1016/j.amjcard.2013.10.018.
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325. Available at: https://doi.org/10.1002/hep.21178.
McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59:1265–1269. Available at: https://doi.org/10.1136/gut.2010.216077.
Hagström H, Nasr P, Ekstedt M, Stål P, Hultcrantz R, Kechagias S. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019;17:1148–1156. Available at: https://doi.org/10.1016/j.cgh.2018.11.030.
Kim SW, Jeon JH, Moon JS, Kim MK. High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study. Endocrinol Metab (Seoul). 2021;36:800–809. Available at: https://doi.org/10.3803/EnM.2021.1040.
Jaruvongvanich V, Wirunsawanya K, Sanguankeo A, Upala S. Nonalcoholic fatty liver disease is associated with coronary artery calcification: A systematic review and meta-analysis. Dig Liver Dis. 2016;48:1410–1417. Available at: https://doi.org/10.1016/j.dld.2016.09.002.
Lee J, Kim HS, Cho YK, Kim EH, Lee MJ, Bae IY, Jung CH, Park JY, Kim HK, Lee WJ. Association between noninvasive assessment of liver fibrosis and coronary artery calcification progression in patients with nonalcoholic fatty liver disease. Sci Rep. 2020;10:18323. Available at: https://doi.org/10.1038/s41598-020-75266-4.
Thévenot T, Vendeville S, Weil D, Akkouche L, Calame P, Canivet CM, Vanlemmens C, Richou C, Cervoni JP, Seronde MF, Di Martino V, Boursier J. Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study. PLoS One. 2022;17:e0266965. Available at: https://doi.org/10.1371/journal.pone.0266965.
Nam GE, Kim YH, Han K, Jung JH, Rhee EJ, Lee SS, et al. Obesity Fact Sheet in Korea, 2019: Prevalence of Obesity and Abdominal Obesity from 2009 to 2018 and Social Factors. J Obes Metab Syndr. 2020;29:124–132. Available at: https://doi.org/10.7570/jomes20058.
Seong JM, Lee JH, Gi MY, Son YH, Moon AE, Park CE, Sung HH, Yoon H. Gender difference in the association of chronic kidney disease with visceral adiposity index and lipid accumulation product index in Korean adults: Korean National Health and Nutrition Examination Survey. Int Urol Nephrol. 2021;53:1417–1425. Available at: https://doi.org/10.1007/s11255-020-02735-0.
Sung HH, Gi MY, Cha JA, Cho HE, Moon AE, Yoon H. Gender difference in the relationship between lipid accumulation product index and pulse pressure in nondiabetic Korean adults: The Korean National Health and Nutrition Examination Survey 2013-2014. Clin Exp Hypertens. 2022;44:146-153. Available at: https://doi.org/10.1080/10641963.2021.2007943.
Wang HW, Peng CY, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, Chen CH, Hsu WF, Huang GT. New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis. Sci Rep. 2017;7:3259. Available at: https://doi.org/10.1038/s41598-017-03589-w.
Ostovaneh MR, Ambale-Venkatesh B, Fuji T, Bakhshi H, Shah R, Murthy VL, Tracy RP, Guallar E, Wu CO, Bluemke DA, Lima JAC. Association of Liver Fibrosis With Cardiovascular Diseases in the General Population: The Multi-Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Imaging. 2018;11:e007241. Available at: https://doi.org/10.1161/CIRCIMAGING.117.007241.
Stundiene I, Sarnelyte J, Norkute A, Aidietiene S, Liakina V, Masalaite L, Valantinas J. Liver cirrhosis and left ventricle diastolic dysfunction: Systematic review. World J Gastroenterol. 2019;25:4779–4795. Available at: https://doi.org/10.3748/wjg.v25.i32.4779.
Dogan S, Celikbilek M, Yilmaz YK, Sarikaya S, Zararsiz G, Serin HI, Borekci E, Akyol L, Pirti I, Davarci SE. Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27:298–304. Available at: https://doi.org/10.1097/MEG.0000000000000286.
Mantovani A, Ballestri S, Lonardo A, Targher G. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1246–1267. Available at: https://doi.org/10.1007/s10620-016-4040-6.
Sibal L, Agarwal SC, Home PD, Boger RH. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev. 2010;6:82–90. Available at: https://doi.org/10.2174/157340310791162659.
Sarmah N, Nauli AM, Ally A, Nauli SM. Interactions among Endothelial Nitric Oxide Synthase, Cardiovascular System, and Nociception during Physiological and Pathophysiological States. Molecules. 2022;27:2835. Available at: https://doi.org/10.3390/molecules27092835.
Pasarín M, Abraldes JG, Liguori E, Kok B, La Mura V. Intrahepatic vascular changes in non-alcoholic fatty liver disease: Potential role of insulin-resistance and endothelial dysfunction. World J Gastroenterol. 2017;23:6777–6787. Available at: https://doi.org/103748/wjg.v23.i37.6777.
Ma Y, Lee G, Heo SY, Roh YS. Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease. Antioxidants (Basel). 2021;11:91. Available at: https://doi.org/103390/antiox11010091.
Cheng XM, Hu YY, Yang T, Wu N, Wang XN. Reactive Oxygen Species and Oxidative Stress in Vascular-Related Diseases. Oxid Med Cell Longev. 2022;2022:7906091. Available at: https://doi.org/101155/2022/7906091.
Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative Stress in Atherosclerosis. Curr Atheroscler Rep. 2017;19:42. Available at: https://doi.org/10.1007/s11883-017-0678-6.
Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol. 2014;20:8407–8415. Available at: https://doi.org/10.3748/wjg.v20.i26.8407.
Watanabe K, Takakubo N, Saigusa T, Nagasawa A, Yamana M, Ojima M, Kameda W, Susa S, Ishizawa K, Hisamitsu I. Fibrosis-4 Index Is Closely Associated with Arterial Damage and Future Risk of Coronary Heart Disease in Type 2 Diabetes. Int J Hypertens. 2022;2022: 2760027. Available at: https://doi.org/10.1155/2022/2760027.
Xin Z, Zhu Y, Wang S, Liu S, Xu M, Wang T, Lu J, Chen Y, Zhao Z, Wang W, Ning G, Bi Y, Xu Y, Li M. Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non-invasive score. Liver Int. 2020;40:806–814. Available at: https://doi.org/10.1111/liv.14322.
Mandraffino G, Morace C, Franzè MS, Nassisi V, Sinicropi D, Cinquegrani M, Saitta C, Scoglio R, Marino S, Belvedere A, Cairo V, Lo Gullo A, Scuruchi M, Raimondo G, Squadrito G. Fatty Liver as Potential Biomarker of Atherosclerotic Damage in Familial Combined Hyperlipidemia. Biomedicines. 2022;10:1770. Available at: https://doi.org/103390/biomedicines10081770.
Sesti G, Sciacqua A, Fiorentino TV, Perticone M, Succurro E, Perticone F. Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis. PLoS One. 2014;9:e104941. Available at: https://doi.org/10.1371/journal.pone.0104941.
Paul, J. Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. Egypt Liver Journal. 2020;10:37. Available at: https://doi.org/10.1186/s43066-020-00043-x.
Long MT, Pedley A, Massaro JM, Hoffmann U, Fox CS. The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study. PLoS One. 2016;11:e0157517. Available at: https://doi.org/10.1371/journal.pone.0157517.
Segers P, Stergiopulos N, Schreuder JJ, Westerhof BE, Westerhof N. Left ventricular wall stress normalization in chronic pressure-overloaded heart: a mathematical model study. Am J Physiol Heart Circ Physiol. 2000;279:1120–1127. Available at: https://doi.org/10.1152/ajpheart.2000.279.3.H1120.
Kelshiker MA, Seligman H, Howard JP, Rahman H, Foley M, Nowbar AN, Rajkumar CA, Shun-Shin MJ, Ahmad Y, Sen S, Al-Lamee R, Petraco R. Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis. Eur Heart J. 2022;43:1582–1593. Available at: https://doi.org/10.1093/eurheartj/ehab775.
Rimoldi O, Rosen SD, Camici PG. The blunting of coronary flow reserve in hypertension with left ventricular hypertrophy is transmural and correlates with systolic blood pressure. J Hypertens. 2014;32:2465–2471. Available at: https://doi.org/10.1097/HJH.0000000000000338.
Yilmaz Y, Kurt R, Yonal O, Polat N, Celikel CA, Gurdal A, Oflaz H, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis. 2010;211:182–186. Available at: https://doi.org/10.1016/j.atherosclerosis.2010.01.049.
McEvoy JW, Chen Y, Rawlings A, Hoogeveen RC, Ballantyne CM, Blumenthal RS, Coresh J, Selvin E. Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control. J Am Coll Cardiol. 2016;68:1713–1722. Available at: https://doi.org/101016/j.jacc.2016.07.754.
Koracevic G, Stojanovic M, Kostic T, Lovic D, Tomasevic M, Jankovic-Tomasevic R. Unsolved Problem: (Isolated) Systolic Hypertension with Diastolic Blood Pressure below the Safety Margin. Med Princ Pract. 2020;29:301–309. Available at: https://doi.org/10.1159/000508462.
Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal NH, Lai M. Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD. Hepatol Commun. 2022;6:765–779. Available at: https://doi.org/10.1002/hep4.1841.
Tomeno W, Imajo K, Takayanagi T, Ebisawa Y, Seita K, Takimoto T, Honda K, Kobayashi T, Nogami A, Kato T, Honda Y, Kessoku T, Ogawa Y, Kirikoshi H, Sakamoto Y, Yoneda M, Saito S, Nakajima A. Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs. Diagnostics (Basel). 2020;10:912. Available at: https://doi.org/10.3390/diagnostics10110912.
Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110:921–937. Available at: https://doi.org/101007/s00392-020-01709-7.
Zhang J, Xu M, Chen T, Zhou Y. Correlation Between Liver Stiffness and Diastolic Function, Left Ventricular Hypertrophy, and Right Cardiac Function in Patients With Ejection Fraction Preserved Heart Failure. Front Cardiovasc Med. 2021;8:748173. Available at: https://doi.org/10.3389/fcvm.2021.748173.
Méndez-Sánchez N, Chavez-Tapia NC, Almeda-Valdes P, Uribe M. The management of incidental fatty liver found on imaging. What do we need to do? Am J Gastroenterol. 2018;113:1274–1276. Available at: https://doi.org/10.1038/s41395-018-0047-2.
Downloads
Publicado
Edição
Seção
Categorias
Licença
Copyright (c) 2025 Nutrición Clínica y Dietética Hospitalaria
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los lectores pueden utilizar los textos publicados de acuerdo con la definición BOAI (Budapest Open Access Initiative)
